首页期刊导航|癌症生物学与医学（英文版）
期刊信息/Journal information
癌症生物学与医学（英文版）
癌症生物学与医学（英文版）

郝希山

季刊

2095-3941

editor@cancerbiomed.org

022-23522919

300060

天津市河西区体院北环湖西路天津市肿瘤医院C座综合楼三楼

癌症生物学与医学（英文版）/Journal Cancer Biology & MedicineCSCDCSTPCD北大核心SCI
查看更多>>Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:● Cancer epigenetics● Cancer stem cell● Improved in vivo and in vitro cancer models● Cancer prevention and epidemiology● Biomarkers for predicting drug response● Mechanism of drug sensitivity and resistance● New approaches for cancer detection and diagnosis● Oncology clinical trials● Targeted therapy● Multidisciplinary treatment for cancerAuthor benefits: ● Easy online submission via Editorial Manager● Efficient and professional peer-review by expert referees from around the world● Rapid pre-print online publication● No charge for publication and Open Access● International visibility - the journal is available free online
正式出版
收录年代

    Weight gain after 35 years of age is associated with increased breast cancer risk:findings from a large prospective cohort study

    Katherine De la TorreWoo-Kyoung ShinHwi-Won LeeDan Huang...
    651-655页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Esophageal cancer global burden profiles,trends,and contributors

    Yi TengChangfa XiaMaomao CaoFan Yang...
    656-666页
    查看更多>>摘要：Objective:This study aimed to provide a comprehensive overview of the global burden of esophageal cancer(EC)and determine the temporal trends and factors influencing changes in the global burden.Methods:The latest incidence and mortality data for EC worldwide were obtained from GLOBALCAN 2022.The mortality and disability-adjusted life years(DALYs)rates for EC from 1990-2019 were sourced from the 2019 Global Burden of Diseases.Trends in EC mortality and DALYs attributable to 11 risk factors or clusters of risk were analyzed using the joinpoint regression model.The trends in age-related EC burden were assessed using a decomposition approach.Results:An estimated 511,054 new cases of EC were diagnosed in 2022 with 445,391 deaths worldwide.Approximately 75%of cases and deaths occurred in Asia.Nearly 50%of global EC deaths and DALYs were attributed to tobacco use in men in 2019,while 20%were attributed to high body mass index(BMI)in women.From 1990-2019,EC deaths and DALYs attributable to almost all risk factors had declining trends,while EC deaths and DALYs attributed to high BMI in men had upward trends.The age-related EC burden exhibited an upward trend driven by population growth and aging,which contributed to 307.4 thousand deaths and 7.2 million DALYs due to EC.Conclusions:The EC burden remains substantial worldwide.Effective tobacco and obesity control measures are critical for addressing the risk-attributable burden of EC.Population growth and aging pose challenges for EC prevention and control efforts.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Global,regional,and national burden of early-onset gastric cancer

    Nuopei TanHongliang WuMaomao CaoFan Yang...
    667-678页
    查看更多>>摘要：Objective:The burden of gastric cancer(GC)across different age groups needs updating.We determined the GC global,regional,and national burden profiles and changes in incidence for 3 sequential 5-year intervals from 2003 to 2017.Methods:The latest incidence and mortality estimates of GC from 185 countries and regions were extracted from the GLOBOCAN 2022 database.The 5-year interval age-standardised incidence rates(ASIRs)were evaluated using cancer registry data from volumes Ⅹ-Ⅻ of the Cancer Incidence in Five Continents(CI5).Correlation analysis was used to evaluate the relationship between ASIR or the age-standardised mortality rate(ASMR)and the Human Development Index(HDI).Results:There was an estimated global 968,000 new GC cases and 660,000 deaths in 2022,with male predominance.GC ASIRs and ASMRs were 9.2 and 6.1 per 100,000 persons,respectively.East Asia had the highest burden,with 53.8％of cases and 48.2％of deaths among all geographic regions.There was a significant correlation between ASIR and HDI.Over three 5-year intervals from 2003 to 2017,the incidence of GC notably decreased in most countries but peaked at 2008-2012 in New Zealand,Turkey,and South Africa.Several countries in Europe,Oceania,and America suggest an increasingly concerning trend among younger individuals,especially females.Conclusions:GC is a significant health issue,especially among males and in geographic regions with an HDI,such as eastern Asia.While the incidence of GC is decreasing in many countries due to prevention efforts and improved treatments,a rising trend persists among younger individuals.Comprehensive prevention strategies tailored to different age patterns are clearly needed.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Attributable liver cancer deaths and disability-adjusted life years in China and worldwide:profiles and changing trends

    Mengdi CaoChangfa XiaMaomao CaoFan Yang...
    679-691页
    查看更多>>摘要：Objective:Liver cancer is a major health concern globally and in China.This analysis investigated deaths and disability-adjusted life years(DALYs)with respect to etiologies and risk factors for liver cancer in China and worldwide.Methods:Global and China-specific data were collected on liver cancer deaths,DALYs,and age-standardized rates(ASRs)from the Global Burden of Disease Study 2019 database.Liver cancer etiologies were classified into five groups and risk factors were categorized into three levels.Each proportion of liver cancer burden was calculated in different geographic regions.The joinpoint regression model were used to assess the trends from 1990-2019.Results:Liver cancer accounted for 484,577 deaths worldwide in 2019 with an ASR of 5.9 per 100,000 population.China had an elevated liver cancer death ASR in 2019 and males had an ASR 1.7 times the global rate.The global ASR for DALYs peaked at 75-79 years of age but peaked earlier in China.Hepatitis B virus was the prominent etiology globally(39.5%)and in China(62.5%),followed by hepatitis C virus and alcohol consumption.In high sociodemographic index countries,non-alcoholic steatohepatitis has gained an increasing contribution as an etiologic factor.The liver cancer burden due to various etiologies has decreased globally in both genders.However,metabolic risk factors,particularly obesity,have had a growing contribution to the liver cancer burden,especially among males.Conclusions:Despite an overall decreasing trend in the liver cancer burden in China and worldwide,there has been a rising contribution from metabolic risk factors,highlighting the importance of implementing targeted prevention and control strategies that address regional and gender disparities.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Impact of cancer diagnosis on life expectancy by area-level socioeconomic groups in New South Wales,Australia:a population-based study

    Md Mijanur RahmanMichael DavidDavid GoldsburyKaren Canfell...
    692-702页
    查看更多>>摘要：Objective:Improvement in cancer survival over recent decades has not been accompanied by a narrowing of socioeconomic disparities.This study aimed to quantify the loss of life expectancy(LOLE)resulting from a cancer diagnosis and examine disparities in LOLE based on area-level socioeconomic status(SES).Methods:Data were collected for all people between 50 and 89 years of age who were diagnosed with cancer,registered in the NSW Cancer Registry between 2001 and 2019,and underwent mortality follow-up evaluations until December 2020.Flexible parametric survival models were fitted to estimate the LOLE by gender and area-level SES for 12 common cancers.Results:Of 422,680 people with cancer,24%and 18%lived in the most and least disadvantaged areas,respectively.Patients from the most disadvantaged areas had a significantly greater average LOLE than patients from the least disadvantaged areas for cancers with high survival rates,including prostate[2.9 years(95%CI:2.5-3.2 years)vs.1.6 years(95%CI:1.3-1.9 years)]and breast cancer[1.6 years(95%CI:1.4-1.8 years)vs.1.2 years(95%CI:1.0-1.4 years)].The highest average LOLE occurred in males residing in the most disadvantaged areas with pancreatic[16.5 years(95%CI:16.1-16.8 years)vs.16.2 years(95%CI:15.7-16.7 years)]and liver cancer[15.5 years(95%CI:15.0-16.0 years)vs.14.7 years(95%CI:14.0-15.5 years)].Females residing in the least disadvantaged areas with thyroid cancer[0.9 years(95%CI:0.4-1.4 years)vs.0.6 years(95%CI:0.2-1.0 years)]or melanoma[0.9 years(95%CI:0.8-1.1 years)vs.0.7 years(95%CI:0.5-0.8 years)]had the lowest average LOLE.Conclusions:Patients from the most disadvantaged areas had the highest LOLE with SES-based differences greatest for patients diagnosed with cancer at an early stage or cancers with higher survival rates,suggesting the need to prioritise early detection and reduce treatment-related barriers and survivorship challenges to improve life expectancy.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Multiple myeloma survival in New South Wales,Australia,by treatment era to 2020

    Eleonora FelettoQingwei LuoAnna KellyMarianne Weber...
    703-711页
    查看更多>>摘要：Objective:Australia has relatively high multiple myeloma(MM)incidence and mortality rates.Advancements in MM treatment over recent decades have driven improvements in MM survival in high-income countries;however,reporting in Australia is limited.We investigated temporal trends in population-wide MM survival across 3 periods of treatment advancements in New South Wales(NSW),Australia.Methods:Individuals with an MM diagnosis in the NSW Cancer Registry between 1985 and 2015 with vital follow-up to 2020,were categorized into 3 previously defined treatment eras according to their diagnosis date(1985-1995,chemotherapy only;1996-2007,autologous stem cell transplantation;and 2008-2015,novel agents including proteasome inhibitors and immunomodulatory drugs).Both relative survival and cause-specific survival according to Fine and Gray's competing risks cumulative incidence function were calculated by treatment era and age at diagnosis.Results:Overall,11,591 individuals were included in the study,with a median age of 70 years at diagnosis.Five-year relative survival improved over the 36-year(1985-2020)study period(31.0%in 1985-1995;41.9%in 1996-2007;and 56.1%in 2008-2015).For individuals diagnosed before 70 years of age,the 5-year relative survival nearly doubled,from 36.5%in 1985-1995 to 68.5%in 2008-2015.Improvements for those>70 years of age were less pronounced between 1985-1995 and 1996-2007;however,significant improvements were observed for those diagnosed in 2008-2015.Similar overall and age-specific patterns were observed for cause-specific survival.After adjustment for gender and age at diagnosis,treatment era was strongly associated with both relative and cause-specific survival(P<0.0001).Conclusions:Survival of individuals with MM is improving in Australia with treatment advances.However,older age groups continue to experience poor survival outcomes with only modest improvements over time.Given the increasing prevalence of MM in Australia,the effects of MM treatment on quality of life,particularly in older age,warrant further attention.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Effectiveness of colorectal cancer screening integrating non-genetic and genetic risk:a prospective study based on UK Biobank data

    Yu ZhangChao ShengZhangyan LyuHongji Dai...
    712-723页
    查看更多>>摘要：Objective:Few studies have evaluated the benefits of colorectal cancer(CRC)screening integrating both non-genetic and genetic risk factors.Here,we aimed to integrate an existing non-genetic risk model(QCancer-10)and a 139-variant polygenic risk score to evaluate the effectiveness of screening on CRC incidence and mortality.Methods:We applied the integrated model to calculate 10-year CRC risk for 430,908 participants in the UK Biobank,and divided the participants into low-,intermediate-,and high-risk groups.We calculated the screening-associated hazard ratios(HRs)and absolute risk reductions(ARRs)for CRC incidence and mortality according to risk stratification.Results:During a median follow-up of 11.03 years and 12.60 years,we observed 5,158 CRC cases and 1,487 CRC deaths,respectively.CRC incidence and mortality were significantly lower among screened than non-screened participants in both the intermediate-and high-risk groups[incidence:HR:0.87,95%confidence interval(CI):0.81-0.94;0.81,0.73-0.90;mortality:0.75,0.64-0.87;0.70,0.58-0.85],which composed approximately 60%of the study population.The ARRs(95%CI)were 0.17(0.11-0.24)and 0.43(0.24-0.61),respectively,for CRC incidence,and 0.08(0.05-0.11)and 0.24(0.15-0.33),respectively,for mortality.Screening did not significantly reduce the relative or absolute risk of CRC incidence and mortality in the low-risk group.Further analysis revealed that screening was most effective for men and individuals with distal CRC among the intermediate to high-risk groups.Conclusions:After integrating both genetic and non-genetic factors,our findings provided priority evidence of risk-stratified CRC screening and valuable insights for the rational allocation of health resources.
      原文链接:
    • NETL
    • NSTL
    • 万方数据